Cancer
Conditions
Brief summary
The long-term goal of this research is to apply technologic approaches to improve the use of oral oncolytics. The objective of this study is to assess patient adherence to oral oncolytics and to validate a currently available smart phone application (iRxReminder) partnered with an automated dispensing device, a Pod, in affecting patient adherence. The rationale for this study is that medication adherence to oncolytics varies and strategies are needed to improve it.
Interventions
OTHERPOD
Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
Oral medication adherence phone application.
Sponsors
University of Michigan Rogel Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must be \> 18 years of age * Must have a smart phone * Must be able to have their oral oncolytic filled at the University of Michigan Comprehensive Cancer Center pharmacy and be newly prescribed Capecitabine (Xeloda).
Exclusion criteria
* Patients who do not have a smart phone * Patients who have a serious mental illness or cognitive impairment, e.g., psychosis or dementia. * Patients who do not speak English * Patients who cannot fill their oral oncolytic prescription at the University of Michigan Comprehensive Cancer Center Pharmacy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change in the number of patients that report high adherence over time via smart phone application alone | 0, 4, 8 and 12 weeks | Adherence will be assessed via smart phone application at baseline, 4, 8 and 12 weeks. Adherence reported via the phone application will be done using an adherence question assessment.This assessment is ordinal in nature and asks the patient to rate their adherence on a scale (poor, fair, good, very good, excellent). |
| The change in the number of patients that report high adherence over time via smart phone application and POD | 0, 4, 8 and 12 weeks | Adherence will be assessed via smart phone application + POD at baseline, 4, 8 and 12 weeks. Adherence reported via the phone application will be done using an adherence question assessment.This assessment is ordinal in nature and asks the patient to rate their adherence on a scale (poor, fair, good, very good, excellent). For the Pod there will be continuous adherence assessed via the pod each time the patient administers or does not administer a scheduled dose. This will be figured into the overall adherence rating. |
| The change in the number of patients that report high adherence over time via telephone/face-to-face visit (self-reported) | 0, 4, 8 and 12 weeks | Adherence will be assessed via telephone/face-to-face visit (self-reported) at baseline, 4, 8 and 12 weeks. Self-reported adherence will be done using an adherence question assessment.This assessment is ordinal in nature and asks the patient to rate their adherence on a scale (poor, fair, good, very good, excellent). |
Countries
United States
Outcome results
None listed